IL6 and melanoma: A study by Tanaka et al. noticed that increased IL6 levels post treatment were found in all 13 patients with malignant melanoma who received nivolumab and had irAEs, while 5 out of 7 patients who did not have irAEs had decreased IL6 levels [62].